Stock overview
Evommune, Inc. (EVMN)
$11.36+0.35%Aft $11.00 (-3.17%)Market cap $409.2M
Stock Scorer
Scoring…
Analyst consensus
$31.14
- Analysts7
- Implied upside+174.1%
- Target range$22.00 to $54.00
Analyst estimates are opinions, not forecasts of what the stock will do.
SEC filings
| Form | Filed | Description |
|---|---|---|
| SCHEDULE 13G | July 16, 2026 | View on EDGAR |
| 4 | July 10, 2026 | PRIMARY DOCUMENT |
| 4 | July 8, 2026 | PRIMARY DOCUMENT |
| 424B3 | June 29, 2026 | 424B3 |
| 8-K | June 29, 2026 | 8-K |
| 4 | June 24, 2026 | PRIMARY DOCUMENT |
| 4 | June 24, 2026 | PRIMARY DOCUMENT |
| 4 | June 24, 2026 | PRIMARY DOCUMENT |
Our EVMN coverage
Frequently asked questions
What do analysts expect for EVMN?
7 analysts cover Evommune, Inc. (EVMN). The consensus rating is Buy and the average price target is $31.14, in a range of $22.00 to $54.00.
Are insiders buying or selling EVMN?
We have no qualifying Form 4 insider purchases or sales on record for Evommune, Inc. (EVMN). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see EVMN SEC filings?
Recent filings are listed on this page, newest first. The latest is a SCHEDULE 13G filed July 16, 2026.
Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.